18F-FDG PET-MRI in patients with uterine cervical cancer - PETRA-C

18F-FDG PET-MRI in patients with uterine cervical cancer - PETRA-C - PETRA-C

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON41355

Enrollment

Registered

2014-09-05

Start date

2016-11-07

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

uterine cervical cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients > 18 years Inoperable cervical cancer, FIGO stage IIb or higher, based on the investigation under anaesthesia Treatment plan: (chemo) radiation with curative intent Informed consent

Exclusion criteria

Exclusion criteria: Tumor relapse Conisation or lymph node dissection in the past Claustrophobia, pregnancy, fasting serum blood sugar >10mmol/l, morbid obesity, standard MRI contraindications and joint prosthesis (as possible cause of attenuation artefacts on PET-CT or PET-MRI)

Design outcomes

Primary

Measure	Time frame
1. Practical aspects of 18F-FDG PET-MRI protocol (e.g. imbedding of our current MRI protocol in the PET-MRI protocol, presence of artifacts, optimal patient preparation) 2. Assessment of the primary tumor: size and FDG uptake on 18F-FDG PET-MRI versus 18F-FDG PET-CT) 3. Lymph node visualisation on 18F-FDG PET-MRI versus 18F-FDG PET-CT (pelvic and paraaortal) 4. Patient comfort during 18F-FDG PET-MRI versus 18F-FDG PET-CT 5. Detection of distant metastases 6. The possibilities of PET-MRI based radiation treatment planning in a PET-MRI system not specially equipped with radiotherapy treatment facilities will be explored.	—

Measure

Time frame

1. Practical aspects of 18F-FDG PET-MRI protocol (e.g. imbedding of our current MRI protocol in the PET-MRI protocol, presence of artifacts, optimal patient preparation) 2. Assessment of the primary tumor: size and FDG uptake on 18F-FDG PET-MRI versus 18F-FDG PET-CT) 3. Lymph node visualisation on 18F-FDG PET-MRI versus 18F-FDG PET-CT (pelvic and paraaortal) 4. Patient comfort during 18F-FDG PET-MRI versus 18F-FDG PET-CT 5. Detection of distant metastases 6. The possibilities of PET-MRI based radiation treatment planning in a PET-MRI system not specially equipped with radiotherapy treatment facilities will be explored.

—

Secondary

Measure	Time frame
n.a.	—

Countries

Netherlands

Outcome results